


Novo Nordisk Region China A/S

c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR number 33 76 13 33

Annual Report 2019

**The Annual Report has been presented and adopted at the Annual
General Meeting on 20 May 2020.**



Chairman of the meeting

Novo Nordisk Region China A/S
Contents

	<u>Page</u>
Management statement and Auditor's report	
Statement by the Board of Directors and Executive Management	3
Independent Auditor's report	4
Management Report	
Company information	6
Management Review	7
Financial Statements 1 January - 31 December 2019	
Income statement	8
Balance sheet	9
Statement of changes in equity	10
Accounting policies	11
Notes	12

Novo Nordisk Region China A/S

Statement by the Board of Directors and Executive Management

Today, the Board of Directors and Executive Management have approved the Annual Report of Novo Nordisk Region China A/S for the year 2019.

The Annual Report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the financial position of the company at 31 December 2019 and the results of the company's operations for 2019 in accordance with the Danish Financial Statements Act.

Further, in our opinion, the Management's review gives a fair review of the development in the company's operations and financial matters and the results of the company's operations and financial position.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Bagsværd, 20 May 2020

Executive Management:



Peter Bøggild

Board of Directors:



Karsten Munk Knudsen
Chairman



Lene Bang



Thomas Haagen

Novo Nordisk Region China A/S

Independent Auditor's report

To the Shareholder of Novo Nordisk Region China A/S

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2019, and of the results of the Company's operations for the financial year 1 January - 31 December 2019 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Novo Nordisk Region China A/S for the financial year 1 January - 31 December 2019, which comprise income statement, balance sheet, statement of changes in equity, summary of significant accounting policies and notes ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Novo Nordisk Region China A/S
Independent Auditor's report

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, 20 May 2020

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
CVR No 33 77 12 31



Mads Melgaard
State Authorised Public Accountant
mne34354



Elife Savas
State Authorised Public Accountant
mne34453

Novo Nordisk Region China A/S
Company information

Company Novo Nordisk Region China A/S
c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR no.: 33 76 13 33
Founded: 14 June 2011
Municipality of domicile: Gladsaxe
Financial year: 1 January – 31 December

Board of Directors Karsten Munk Knudsen, chairman
Lene Bang
Tomas Haagen

Executive Management Peter Bøggild

Auditors PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
2900 Hellerup
Denmark

General Meeting The Annual General Meeting will be held on 20 May 2020 at the company's address.

Novo Nordisk Region China A/S Management Review

Main activities

There has been no activity in the company in 2019.

Development during the financial year

Net loss for Novo Nordisk Region China A/S ended at DKK 23 thousand for the year 2019 compared to a loss of DKK 19 thousand for the year 2018.

Events after the balance sheet date

No events have occurred after the end of the reporting period that materially affect the financial position of the company.

Governments across the world have decided to initiate measures as a response to the COVID-19 outbreak. The measures were initiated after the balance sheet date (31 December 2019). The Management therefore considers the implications of COVID-19 a non-adjusting subsequent event to the Company. The implications of COVID-19 is not expected to have a material impact on the company's revenue and earnings for 2020.

Novo Nordisk Region China A/S
Income statement

	Note	2019 DKK '000	2018 DKK '000
Administrative costs		29	25
Operating profit/(loss)		(29)	(25)
Financial income	1	-	1
Financial expenses	2	1	-
Profit/(loss) before income taxes		(30)	(24)
Income taxes		(7)	(5)
NET PROFIT/(LOSS) FOR THE YEAR	3	(23)	(19)

For proposed appropriation of net profit see note 3.

Novo Nordisk Region China A/S
Balance sheet at 31 December

	Note	2019 DKK '000	2018 DKK '000
ASSETS			
Amounts owed by affiliated companies		380	400
Tax receivables		7	7
Cash at bank		12	15
TOTAL CURRENT ASSETS		399	422
TOTAL ASSETS		399	422
EQUITY AND LIABILITIES			
Share capital	4	500	500
Retained earnings		(127)	(104)
TOTAL EQUITY		373	396
Other liabilities		26	26
TOTAL CURRENT LIABILITIES		26	26
TOTAL LIABILITIES		26	26
TOTAL EQUITY AND LIABILITIES		399	422

Novo Nordisk Region China A/S

Statement of changes in equity at 31 December

	Share capital DKK '000	Retained earnings DKK '000	Total DKK '000
2019			
Balance at the beginning of the year	500	(104)	396
Net profit/(loss) for the year		(23)	(23)
Balance at the end of the year	500	(127)	373
2018			
Balance at the beginning of the year	500	(85)	415
Net profit/(loss) for the year		(19)	(19)
Balance at the end of the year	500	(104)	396

Novo Nordisk Region China A/S
Accounting policies

Accounting basis

The Annual Report of the company is prepared in accordance with the Danish Financial Statements Act for a class B enterprise as well as selected rules applying to reporting class C.

The accounting policies applied remain unchanged from last year.

The Annual Report is presented in DKK 1,000.

Translation of foreign currencies

Assets and debt in foreign currencies are translated into Danish kroner at the exchange rates at the balance sheet date.

Administrative costs

Administrative costs consists of audit fee for auditing of the annual report.

Financial items

Financial income and expenses include interest income and expenses, realised and unrealised capital gains and losses on debt and transactions in foreign currencies as well as amortisation of financial assets and liabilities. Financial income and expenses are recognised by the amounts pertaining to the financial year.

Amounts owed by affiliated companies

Receivables are stated at amortised cost less write-downs for potential losses on doubtful debts. The write-downs are based on an individual assessment of each debtor.

Tax

The company is jointly taxed with the Danish companies in the Novo Holdings A/S Group. The tax effect of the joint taxation with the parent company and other subsidiaries is allocated to the companies in proportion to their taxable incomes (full allocation). The current tax in the joint taxation is paid by the ultimate parent company, Novo Holdings A/S, which functions as the tax administration company. The jointly taxed Danish enterprises have adopted the on-account taxation scheme.

Short-term debt

Short-term debt are measured at amortised cost.

Dividends

Proposed dividends (not yet declared) for the accounting period are recognised in the equity as proposed dividends.

Novo Nordisk Region China A/S
Notes

1 - Financial income	2019	2018
	DKK '000	DKK '000
Foreign exchange rate gain (net)	-	1
Total financial income	-	1

2 - Financial expenses	2019	2018
	DKK '000	DKK '000
Other financial expenses	1	-
Total financial expenses	1	-

3 - Proposed appropriation of the net profit	2019	2018
	DKK '000	DKK '000
Retained earnings	(23)	(19)
Distribution of net profit/(loss)	(23)	(19)

4 - Share capital

The share capital consists of 5,000 shares of nominal value DKK 100.

5 - Contingencies

The company is jointly taxed with the Danish companies in the Novo Holdings A/S Group. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is allocated in full on the basis of the expected taxable income.

The company has no other contingent liabilities.

6 - Related parties and ownership

Controlling interest	Basis
Novo Nordisk Region AAMEO and LATAM A/S, Novo Allé, 2880 Bagsværd Denmark	Principal shareholder, owns 100%
Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark	Controls Novo Nordisk Region AAMEO and LATAM A/S
Novo Holdings A/S, Tuborg Havnevej 19, 2900 Hellerup, Denmark	Controls Novo Nordisk A/S
Novo Nordisk Foundation, Tuborg Havnevej 19, 2900 Hellerup, Denmark	Ultimate parent of the Group

The company is included in the consolidated financial statements of Novo Nordisk A/S.